NHS Trusts Question Value of Palantir Data Platform

Several NHS organisations in England are choosing not to use a patient data platform developed by the US technology company Palantir. Information obtained through freedom of information requests suggests that some health bodies believe existing software can meet their needs just as well. The findings have renewed debate over a major technology contract and the use of private companies in public healthcare.

The Federated Data Platform was designed to help health services bring information together and improve the management of care. Its supporters say the system can help hospitals plan operations, manage waiting lists and reduce delays when patients leave hospital. Better use of information can help staff see where resources are needed and coordinate work across different teams.

However, not every NHS organisation has found the platform useful. Some trusts said it did not offer enough improvement over their current systems, while others tested it and later returned to previous arrangements. The responses show that a single technology solution may not work equally well for every hospital or health board.

The contract is worth hundreds of millions of pounds and has attracted political attention. Critics have raised concerns about the company's other work and the risks of giving a private technology firm a larger role in public services. Some campaigners also question whether the claimed benefits have been measured clearly enough to justify continued use.

Palantir has defended the platform and says many NHS organisations have reported improvements. NHS England has also said that trusts using the system have seen benefits, including more efficient work and better coordination. Yet officials have cautioned that reported improvements cannot always be linked to the software alone because other factors may affect results.

The government faces a decision about whether to continue with the agreement or use a break clause. That decision must weigh the cost of the system, the evidence of its benefits, the effort needed to change software and the public's trust in how health data is handled.

The debate is not simply about one technology company. It raises a wider question about how public services should buy digital tools and prove that they deliver value. Any long-term choice will need to balance patient privacy, practical improvements for staff and responsible use of public money.